Skip to content

ETHERNA IMMUNOTHERAPIES

Active Public limited companyfounded 2013active for 13 yearsGalileilaan 19, 2845 NielKBO/BCE: BE 0502.703.389 subsidiary of PROGRESS PHARMA#3 company by total assets in Niel, Professional and technical services sector
ETHERNA IMMUNOTHERAPIES
Follow ReportCompare

Board

3 directors, 1 in day-to-day management, 1 auditor, last change in October 2026
21-23 NEWELL ROAD LLC
Independent director, permanent representative Philip Chase
since 25-04-2023 6-year term from 2023
listed in the 2025 annual accounts, filed on 29-05-2026
Inphacon BV
Director and CEO, permanent representative SAGAERT Bernard
director since 25-10-2024 CEO appointed by deed of 05-10-2022 term until 25-10-2030, term without a fixed end
listed in the 2025 annual accounts, filed on 29-05-2026
Valerio Therapeutics
Sole director (not named in the articles), permanent representative BESIN Gilles
appointed by deed of 19-10-2026 5-year term from 2026
BV PwC Bedrijfsrevisoren
Statutory auditor, permanent representative Didier Delanoye
current term since 23-10-2024 term until 27-04-2027
listed in the 2025 annual accounts, filed on 29-05-2026
Inphacon BV
Signing authorityThe articles say who may bind the company, for example by signing a contract.
The sole director
deed of 19-10-2026
Permanent representatives 3
Philip Chase
Permanent representative, for 21-23 NEWELL ROAD LLC
appointed by deed of 16-06-2023
BESIN Gilles
Permanent representative, for Valerio Therapeutics
appointed by deed of 19-10-2026
SAGAERT Bernard
Permanent representative, for Inphacon BV
appointed by deed of 05-10-2022

Office holders in the KBO →

Mandates through the years

21 names, the dashed line is today
Show
21-23 NEWELL ROAD LLC
Independent director
Valerio Therapeutics
Sole director (not named in the articles)
Inphacon BV
Interim ceo en persoon belast met het dagelijks bestuur
BV PwC Bedrijfsrevisoren
Statutory auditor
Antonin de Fougerolles
Independent director
BIOTECH FONDS VLAANDEREN
Director
CHIEN Kenneth Randall
Director
DE KONING John
Director
DEKKERS Marinus Emmanuel
Director
Marijn Dekkers
Chair
Greig Biotechnology Global Consulting Inc.
Independent director
The Truffaldino Partnership Limited
Director
Chris BUYSE
Director
Participatiemaatschappij Vlaanderen
Director
ViaNova BV
Independent director
Vincent OSSIPOW
Director
Yijun CHEN
Director
Ni Xie
Director
KALKBRENNER Frank Axel
Director
Alexandra Tolia
Director
Deloitte Bedrijfsrevisoren/Réviseurs d’Entreprises
Statutory auditor
LeadershipBoardEarlierRest of the termmandate already running before its first mentionend not dated
Mandates as a list
  • 21-23 NEWELL ROAD LLC
    • Independent director, from 25-04-2023 to date
  • Valerio Therapeutics
    • Sole director (not named in the articles), appointed by deed of 19-10-2026, still in office
  • Inphacon BV
    • Director, appointed by deed of 05-10-2022, until 08-10-2026
    • Interim ceo en persoon belast met het dagelijks bestuur, appointed by deed of 05-10-2022, still in office
  • BV PwC Bedrijfsrevisoren
    • Statutory auditor, from 02-12-2021 to date
  • Antonin de Fougerolles
    • Independent director, appointed by deed of 06-04-2023, until 08-10-2026
    • Chair of the board, appointed by deed of 05-11-2024, ended, last mentioned on 05-11-2024
  • BIOTECH FONDS VLAANDEREN
    • Director, appointed by deed of 22-08-2022, until 08-10-2026
  • CHIEN Kenneth Randall
    • Director, appointed by deed of 22-08-2022, until 08-10-2026
  • DE KONING John
    • Director, from 21-03-2016 to 08-10-2026
  • DEKKERS Marinus Emmanuel
    • Director, appointed by deed of 22-08-2022, until 08-10-2026
  • Marijn Dekkers
    • Chair, appointed by deed of 10-06-2024, no longer listed in the 2025 annual accounts
  • Greig Biotechnology Global Consulting Inc.
    • Independent director, from 01-09-2016 to 22-09-2023
  • The Truffaldino Partnership Limited
    • Director, from 25-10-2018 to 05-10-2022
    • CEO and day-to-day manager, until 10-08-2022
  • Chris BUYSE
    • Director, from before 31-12-2021 to 22-08-2022
  • Participatiemaatschappij Vlaanderen
    • Director, from 30-04-2020 to 22-08-2022
  • ViaNova BV
    • Independent director, from 21-03-2016 to 22-08-2022
    • Independent director, appointed by deed of 29-07-2022, no longer listed in the 2025 annual accounts
  • Vincent OSSIPOW
    • Director, from 21-03-2016 to 22-08-2022
  • Yijun CHEN
    • Director, from 12-06-2020 to 22-08-2022
  • Ni Xie
    • Director, from 12-06-2020 to 21-04-2022
  • KALKBRENNER Frank Axel
    • Director, appointed by deed of 03-12-2021, until 14-04-2022
  • Alexandra Tolia
    • Director, from 25-10-2018 to 25-03-2022
  • Deloitte Bedrijfsrevisoren/Réviseurs d’Entreprises
    • Statutory auditor, appointed by deed of 07-02-2022, until 07-02-2022

Control

Parent
PROGRESS PHARMA
Equity €47,137
Loss €5,479 in 2025 (loss €2,921 in 2024)
Checked score 93
100%
This company
ETHERNA IMMUNOTHERAPIES
Equity -€3.9m
Loss €4.3m in 2025

and 2 other shareholders

Capital

Capital
€1,979,105.59
Shares
1,478,585
Contribution per share
€1.34
Equity per share
-€2.64 in 2025
Source
deed of 19-10-2026

Owners through the years

as the annual accounts name them
PROGRESS PHARMA
14.3%2.37%100%
100%
Fund+
5.27%
16.7%
Participatiemaatschappij Vlaanderen
17.49%13.4%11.09%
11.09%
Owners as a list

Source: lists of holdings in the owners' accounts

Articles of association

DurationMost companies exist for an unlimited period, until they are dissolved.
Unlimited
deed of 19-10-2026 (in Dutch)
Board ruleThese rules set how the board is made up, meets and takes decisions.
1 director
deed of 19-10-2026 (in Dutch)
Kind of sharesThe articles set which classes of shares exist and what rights each class carries.
“Inschrijvings- en aandeelhoudersovereenkomst van 2022-07-30, Bevoorrechte Aandelen”
deed of 22-08-2022 (in Dutch)
Annual meetingThe shareholders approve the annual accounts, among other things, at the annual meeting.
Fourth Tuesday of April at 16:00
deed of 19-10-2026 (in Dutch)
Dissolution ruleThe articles set when and by whom the company can be dissolved.
“In de bij wet bepaalde gevallen, besluit van de algemene vergadering”
deed of 19-10-2026 (in Dutch)
Liquidation ruleIn a liquidation the creditors are paid first. What is left goes to the shareholders.
“Algemene vergadering kan te allen tijde deze bevoegdheden bij gewone meerderheid beperken, aandeelhouders verdelen het liquidatiesaldo met…”
deed of 19-10-2026 (in Dutch)

Shareholders

3 owners

Owners 3

Capital transactions

Capital over time
  1. 19-10-2026 Capital stated in the deed · €1,979,105.59 · 1,478,585 shares
  2. 18-03-2025 Capital increase of €550.74 · to €1,979,105.59 · 411 new shares · “uitoefening van 411 Stock Optie Warrants”
  3. 22-08-2022 Capital increase of €382,038.86 · to €1,667,258.92 · 285,421 new shares · in cash
  4. 22-08-2022 Capital increase of €200,445.89 · to €1,867,704.81 · 149,753 new shares · in kind
  5. 22-08-2022 Capital increase of €110,850.04 · to €1,978,554.85 · 82,816 new shares, 5.6% of the 1,478,174 shares after the increase · in kind
  6. 22-08-2022 Capital increase of €29,906,957.29 · to €31,885,512.14 · no new shares · from reserves
  7. 22-08-2022 Capital reduction of €29,906,957.29 · to €1,978,554.85 · “aanzuivering van werkelijk geleden verliezen”
  8. 04-02-2021 Capital increase of €11,164,320 · to €12,203,770.09 · no new shares · from reserves
Show 3 older capital entries
  1. 04-02-2021 Capital reduction of €11,164,320 · to €1,039,450.09 · “incorporatie van werkelijk geleden verliezen in het kapitaal”
  2. 04-02-2021 Capital increase of €245,769.97 · to €1,285,220.06 · 183,614 new shares, 19.1% of the 960,184 shares after the increase
  3. 11-08-2020 Capital increase of €47,264.28 · to €1,039,450.09 · 35,311 new shares · in cash

Next steps

See this company's board, registered office and name on a given date.Company as of a date See what became of the directors' other companies.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file

We would like to set cookies. That happens only with your consent. What we measure